GlassScriptPhysician profile
Russell C Maxa
NPI 1699784785
$6,027.66
in general payments reported to CMS, 2019-2025
41 companies · $798 in 2025
The $798 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $928 · 2020: $544 · 2021: $1,307 · 2022: $770 · 2023: $733 · 2024: $948 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,478.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,420.27 | 2019-2025 | |
| Novo Nordisk INC | $1,013.18 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $694.50 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $336.18 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $284.26 | 2022-2025 | |
| Lilly USA, LLC | $237.28 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $205.93 | 2019-2024 | Airsupra |
| Amarin Pharma, INC. | $182.09 | 2021-2022 | |
| Allergan, INC. | $179.35 | 2020 | |
| Glaxosmithkline, LLC. | $125.87 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Celgene Corporation | $116.03 | 2019-2023 | Zeposia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.15 | 2019-2023 | Ofev |
| Dexcom, INC. | $100.11 | 2022-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $93.44 | 2021-2024 | Veozah |
| Esperion Therapeutics, INC. | $89.86 | 2020-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Maxa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.